Track topics on Twitter Track topics that are important to you
Allegro Ophthalmics' Luminate integrin peptide therapy has passed a phase 2 trial in diabetic macular edema (DME) patients by meeting its primary endpoint when used as a sequential treatment.
Original Article: Allegro’s Luminate succeeds in phase 2 diabetic macular edema trialNEXT ARTICLE
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...